Am. J. Respir. Crit. Care Med., Volume 162, Number 4, October 2000, 1493-1499

Imbalance between Platelet Vascular Endothelial Growth Factor and Platelet-derived Growth Factor in Pulmonary Hypertension
Effect of Prostacyclin Therapy

SAADIA EDDAHIBI, MARC HUMBERT, SAID SEDIAME, CHRISTOS CHOUAID, CHOHREH PARTOVIAN, BERNARD MAÎTRE, EMMANUEL TEIGER, DOMINIQUE RIDEAU, GERALD SIMONNEAU, OLIVIER SITBON, and SERGE ADNOT

Department de Physiologie and INSERM U 492, Hôpital H Mondor, AP-HP, Créteil, France; Service de Pneumologie, Hôpital A Béclère, AP-HP, Clamart, France; and Service de Pneumologie, Hôpital Intercommunal, Créteil, France

Focal vascular injury and impaired endothelial function are features of pulmonary hypertension (PH) that lead to enhanced platelet endothelial cell interactions. Vascular endothelial growth factor (VEGF) is contained in platelets and released at sites of vascular injury to promote endothelial repair and wound healing in combination with platelet-derived nonspecific mitogens such as platelet-derived growth factor (PDGF). The overall balance between platelet VEGF and PDGF was investigated in 21 patients with primary PH, 8 with secondary PH, and 27 with chronic hypoxemic lung disease (CHLD), as well as in 29 control subjects. Platelet VEGF content was increased in patients with primary and secondary PH as compared with control subjects (518 ± 89, 675 ± 156, and 166 ± 29 fg/10⁵ platelets, respectively; p < 0.01), whereas platelet PDGF content was similar in the three groups (31 ± 2, 36 ± 4, and 33 ± 3 pg/10⁵ platelets, respectively; NS). Patients treated with a continuous prostacyclin infusion had a higher platelet VEGF but a similar platelet PDGF content as compared with untreated patients. Moderate increases in platelet VEGF and PDGF contents were observed in the CHLD patients. We conclude that patients with primary or secondary PH have an increase in platelet VEGF content, but not in platelet PDGF content, and that their platelet VEGF content increases further in response to prostacyclin infusion. We suggest that imbalance between platelet VEGF and PDGF is beneficial to patients with PH.

This article has been cited by other articles:

				N. Selimovic, C-H. Bergh, B. Andersson, E. Sakiniene, H. Carlsten, and B. Rundqvist Growth factors and interleukin-6 across the lung circulation in pulmonary hypertension Eur. Respir. J., September 1, 2009; 34(3): 662 - 668. [Abstract] [Full Text] [PDF]

				P. M. Hassoun, L. Mouthon, J. A. Barbera, S. Eddahibi, S. C. Flores, F. Grimminger, P. L. Jones, M. L. Maitland, E. D. Michelakis, N. W. Morrell, et al. Inflammation, growth factors, and pulmonary vascular remodeling. J. Am. Coll. Cardiol., June 30, 2009; 54(1 Suppl): S10 - S19. [Abstract] [Full Text] [PDF]

				H. A. Ghofrani, R. J. Barst, R. L. Benza, H. C. Champion, K. A. Fagan, F. Grimminger, M. Humbert, G. Simonneau, D. J. Stewart, C. Ventura, et al. Future perspectives for the treatment of pulmonary arterial hypertension. J. Am. Coll. Cardiol., June 30, 2009; 54(1 Suppl): S108 - S117. [Abstract] [Full Text] [PDF]

				D. Montani, L. Achouh, A. G. Marcelin, J-P. Viard, O. Hermine, D. Canioni, O. Sitbon, G. Simonneau, and M. Humbert Reversibility of pulmonary arterial hypertension in HIV/HHV8-associated Castleman's disease Eur. Respir. J., November 1, 2005; 26(5): 969 - 972. [Abstract] [Full Text] [PDF]

				T. M. Bull, C. D. Coldren, M. Moore, S. M. Sotto-Santiago, D. V. Pham, S. P. Nana-Sinkam, N. F. Voelkel, and M. W. Geraci Gene Microarray Analysis of Peripheral Blood Cells in Pulmonary Arterial Hypertension Am. J. Respir. Crit. Care Med., October 15, 2004; 170(8): 911 - 919. [Abstract] [Full Text] [PDF]

				J. K. Damas, K. Otterdal, A. Yndestad, H. Aass, N. O. Solum, S. S. Froland, S. Simonsen, P. Aukrust, and A. K. Andreassen Soluble CD40 Ligand in Pulmonary Arterial Hypertension: Possible Pathogenic Role of the Interaction Between Platelets and Endothelial Cells Circulation, August 24, 2004; 110(8): 999 - 1005. [Abstract] [Full Text] [PDF]

				R. Budhiraja, R. M. Tuder, and P. M. Hassoun Endothelial Dysfunction in Pulmonary Hypertension Circulation, January 20, 2004; 109(2): 159 - 165. [Full Text] [PDF]

				M.-A. Pascaud, F. Griscelli, W. Raoul, E. Marcos, P. Opolon, B. Raffestin, M. Perricaudet, S. Adnot, and S. Eddahibi Lung Overexpression of Angiostatin Aggravates Pulmonary Hypertension in Chronically Hypoxic Mice Am. J. Respir. Cell Mol. Biol., October 1, 2003; 29(4): 449 - 457. [Abstract] [Full Text] [PDF]

				C. D. Cool, P. R. Rai, M. E. Yeager, D. Hernandez-Saavedra, A. E. Serls, T. M. Bull, M. W. Geraci, K. K. Brown, J. M. Routes, R. M. Tuder, et al. Expression of Human Herpesvirus 8 in Primary Pulmonary Hypertension N. Engl. J. Med., September 18, 2003; 349(12): 1113 - 1122. [Abstract] [Full Text] [PDF]

				T.M. Bull, C.D. Cool, A.E. Serls, P.R. Rai, J. Parr, J.M. Neid, M.W. Geraci, T.B. Campbell, N.F. Voelkel, and D.B. Badesch Primary pulmonary hypertension, Castleman's disease and human herpesvirus-8 Eur. Respir. J., September 1, 2003; 22(3): 403 - 407. [Abstract] [Full Text] [PDF]

				L. H. Caramuru, R. D. P. S. Soares, N. Y. Maeda, and A. A. Lopes Hypoxia and Altered Platelet Behavior Influence von Willebrand Factor Multimeric Composition in Secondary Pulmonary Hypertension Clinical and Applied Thrombosis/Hemostasis, July 1, 2003; 9(3): 251 - 258. [Abstract] [PDF]

				S. Eddahibi, N. Morrell, M-P. d'Ortho, R. Naeije, and S. Adnot Pathobiology of pulmonary arterial hypertension Eur. Respir. J., December 1, 2002; 20(6): 1559 - 1572. [Abstract] [Full Text] [PDF]

				M.M. Hoeper Pulmonary hypertension in collagen vascular disease Eur. Respir. J., March 1, 2002; 19(3): 571 - 576. [Abstract] [Full Text] [PDF]

				M. J. TOBIN Chronic Obstructive Pulmonary Disease, Pollution, Pulmonary Vascular Disease, Transplantation, Pleural Disease, and Lung Cancer in AJRCCM 2000 Am. J. Respir. Crit. Care Med., November 15, 2001; 164(10): 1789 - 1804. [Full Text] [PDF]